Publication | Closed Access

O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION

Hcv InfectionViral HepatitisImmunologyAntiviral Drug DevelopmentHepatitisVirologyAntiviral TherapyInfection ControlAntiviral DrugMedicineClinical Microbiology